C12N 2760/18152
Relating to complementing cells and packaging systems for producing virus or viral
Official title: relating to complementing cells and packaging systems for producing virus or viral particles
C12N2760/18152 (Relating to complementing cells and packaging systems for producing virus or viral) appears on 10 US grants and 14 published applications in this corpus.
Search patents in C12N- Granted patents
- 10
- Published applications
- 14
- Assignees
- 8
- Inventors
- 31
- Latest grant
- 30 Jan 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 2 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 2 |
| 2013 | 1 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 1 |
| 2016 | 1 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 0 |
| 2022 | 2 | 3 |
| 2023 | 0 | 2 |
| 2024 | 1 | 1 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Oncolytic virus for colorectal cancer treatment using colorectal cancer cell-specific infectious newcastle disease virus and composition for colorectal cancer treatment using same30 Jan 2024US 11,884,931 B2Libentech Co., Ltd.
- Oncolytic virus for treating brain tumors using recombinant Newcastle disease virus into which Newcastle disease virus vector-based PTEN gene is inserted and composition for treating brain tumors using same20 Dec 2022US 11,530,422 B2Libentech Co., Ltd.
- Enveloped virus resistant to complement inactivation for the treatment of cancer15 Mar 2022US 11,274,141 B2Wellstat ImmunoTherapeutics, LLC
- Vaccine composition for preventing human infection of SARS coronavirus and alleviating infection symptoms23 Nov 2021US 11,179,459 B1Libentech Co., Ltd.
- Newcastle disease virus vectored herpesvirus vaccines20 Sep 2016US 9,446,118 B2Merial Limited
- Newcastle Disease Virus with Improved Heat Resistance, and Newcastle Disease Virus Vaccine Comprising Same5 Mar 2026US 2026/0061047 A1Biopoa, Inc.
- Recombinant newcastle disease virus and preparation method therefor, recombinant plasmid, and use thereof15 Aug 2024US 2024/0271106 A1Jiangsu Kanionreal Biomedical Technology Co., Ltd
- Recombinant oncolytic newcastle disease viruses with increased activity22 Jun 2023US 2023/0193213 A1
- Oncolytic virus for colorectal cancer treatment using colorectal cancer cell-specific infectious newcastle disease virus and composition for colorectal cancer treatment using same20 Apr 2023US 2023/0121063 A1Libentech Co., Ltd.
- Oncolytic virus for treating brain tumors using recombinant newcastle disease virus into which newcastle disease virus vector-based pten gene is inserted and composition for treating brain tumors using same17 Nov 2022US 2022/0364112 A1Libentech Co., Ltd.
Most cited
By later US patents
- Helper-free rescue of recombinant negative strand RNA viruses97US 6,544,785 B1Mount Sinai School of Medicine of New York University · 2003
- Helper-free rescue of recombinant negative strand RNA virus78US 6,649,372 B1Mount Sinai School of Medicine of New York University · 2003
- Helper-free rescue of recombinant negative strand RNA virus30US 7,384,774 B2Mount Sinai School of Medicine of New York University · 2008
- Recombinant avian paramyxovirus vaccine and method for making and using thereof2US 8,486,418 B2Merial Limited · 2013
- Newcastle disease virus vectored herpesvirus vaccines2US 8,986,706 B2Merial Limited · 2015